Pharma BD Deal Intelligence
AstraZeneca's up-to-$1 billion buy of EsoBiotec ($425 million upfront) landed real signal: a 5-patient Nature Medicine readout on ESO-T01 showed 4 of 5 objective responses including 3 stringent complete remissions, but every patient had grade 3 or higher serious adverse events and one died.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AstraZeneca is paying $425 million up front to acquire Esobiotec S.A., a Belgian company that has generated early clinical evidence in China for an in vivo…
AstraZeneca said Monday that it has agreed to acquire a cell therapy biotech founded just four years ago for an upfront payment of $425 million. The British…
AstraZeneca plc has agreed to pay up to $1 billion to acquire privately held EsoBiotec SA, a Belgian biotech developing in vivo CAR-T therapies. The…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
AstraZeneca acquired Belgian biotech EsoBiotec for up to $1B ($425M upfront + $575M in development/regulatory milestones, cash- and debt-free), announced 17 Mar 2025 and completed 20 May 2025. The deal brings EsoBiotec's ENaBL (Engineered NanoBody Lentiviral) platform for in vivo CAR-T, which uses a nanobody-targeted, immune-shielded lentiviral vector to reprogram T cells inside the patient in a single IV infusion, avoiding leukapheresis, ex vivo manufacturing and lymphodepleting chemotherapy. Lead asset ESO-T01 (anti-BCMA) was tested in an investigator-initiated Phase 1 study in relapsed/refractory multiple myeloma in Wuhan, China. Published in Nature Medicine (2026), the 5-patient readout showed 4 of 5 objective responses including 3 stringent complete remissions at a median ~6-month follow-up. However, all patients experienced grade 3 or higher serious adverse events and one patient died (attributed by investigators to disease progression / spinal-cord compression, with timing near peak CAR-T expansion); the trial was stopped early in 2025 with no further enrollment. The data establish proof-of-concept for in vivo CAR-T generation while underscoring tolerability questions AstraZeneca must resolve as it advances the platform.
36K US cases/yr · $25.0B Global multiple myeloma therapeutics market 2024 (~$25B) · 2 Approved ex vivo CAR-T therapies in MM (Abecma, Carvykti)
Multiple myeloma (MM) is an incurable plasma cell malignancy with approximately 35,730 new US cases and 12,590 deaths estimated in 2024 (ACS). Treatment has advanced dramatically over two decades — proteasome inhibitors, IMiDs, anti-CD38 monoclonals, and most recently BCMA- and GPRC5D-directed CAR-T cells and bispecifics have transformed relapsed/refractory outcomes. However, autologous ex vivo CAR-T (Abecma, Carvykti) carries significant manufacturing complexity, 3-6 week vein-to-vein times, lymphodepletion requirements, cytokine release syndrome and ICANS toxicity risks, and limited accessibility outside specialized centers. In vivo CAR-T — engineering T cells inside the patient via targeted lentiviral or lipid nanoparticle delivery — promises to collapse manufacturing, reduce cost, and democratize access. EsoBiotec's ENaBL (Engineered NanoBody Lentiviral) platform uses surface-engineered lentiviral vectors displaying nanobodies that target specific immune cells in vivo, reprogramming T cells without ex vivo manipulation. Early clinical data in Chinese investigator-initiated trials (with collaborator Shanghai-based Shenzhen Amkey) reportedly showed anti-BCMA in vivo CAR-T responses in heavily pretreated multiple myeloma. Broader applicability extends to lymphomas, autoimmune diseases (lupus, myositis), and solid tumors where T cell reprogramming is therapeutically relevant.
The in vivo CAR-T competitive landscape is emerging and highly strategic. Approved ex vivo CAR-T benchmarks include Abecma (idecabtagene vicleucel, BMS/2seventy bio — BCMA) and Carvykti (ciltacabtagene autoleucel, J&J/Legend — BCMA), both in relapsed/refractory multiple myeloma; and Yescarta, Kymriah, Breyanzi (CD19-directed) for lymphomas. Bispecifics competing in the same patient segment include Tecvayli (teclistamab, J&J — BCMAxCD3), Elrexfio (elranatamab, Pfizer — BCMAxCD3), and Talvey (talquetamab, J&J — GPRC5DxCD3). In vivo CAR-T competitors to EsoBiotec's ENaBL platform include Umoja Biopharma (VivoVec lentiviral platform), Capstan Therapeutics (tLNP mRNA CAR-T — acquired by AbbVie June 2025 for $2.1B), Orna Therapeutics (circular RNA LNP CAR), Interius BioTherapeutics (lentiviral in vivo CAR-T), EnGene (mRNA-LNP delivery), and Poseida Therapeutics (non-viral transposon CAR-T). AstraZeneca's acquisition of EsoBiotec positions it alongside AbbVie's Capstan play in the two highest-profile in vivo CAR-T M&A transactions of 2025, signaling that major pharmas view this modality as the next-generation cell therapy platform and strategic hedge against ex vivo CAR-T limitations.
Nature Medicine published the first-in-human in vivo anti-BCMA CAR-T (ESO-T01) Phase 1 in 5 R/R multiple myeloma patients: single IV infusion, no leukapheresis/lymphodepletion. 4/5 objective responses incl 3 stringent CRs at median ~6mo. All patients had grade 3+ SAEs; one death (investigators attribute to disease progression). Trial stopped early in 2025.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / EsoBiotec SA (this deal) | 2025 | $1.0B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2025 deals · AstraZeneca PLC deals · Hematology deals